FDA Warns Beckman Coulter On Marketing Of "AccuTnI" Heart Test

Date : 07/06/2010 @ 3:19PM
Source : Dow Jones News
Stock : Beckman Coulter, Inc. (BEC)
Quote : 83.47  0.0 (0.00%) @ 2:05AM

FDA Warns Beckman Coulter On Marketing Of "AccuTnI" Heart Test

Beckman Coulter (NYSE:BEC)
Historical Stock Chart

5 Years : From Apr 2012 to Apr 2017

Click Here for more Beckman Coulter Charts.

The Food and Drug Administration said a Beckman Coulter Inc. (BEC) heart test was illegally being marketed without agency clearance.

In a June 21 warning letter sent to the company, the FDA said the firm's "AccuTnI on the Access Immunoassay System" is considered a medical device intended for use in the diagnosis of disease. The warning letter was posted to FDA's website Tuesday. The product is designed to test for a protein called troponin I, which is considered a marker for heart problems.

In April, the company had said it would remove the AccuTnI Troponin kits from its UniCel Dxl immunoassay system after the FDA had said the tests required agency approval. It's not immediately clear if the UniCel system is different from the access immunoassay system referenced in the FDA letter.

Neither the FDA nor the company immediately returned requests for comment.

-By Jennifer Corbett Dooren and Jon Kamp, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com

 
 



Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.